Pharmsintez and the Almazov Center agreed on cooperation in the creation of an innovative drug

2023: Agreement to create a drug for personalized diagnosis and treatment of brain malignancies

The portfolio company Rusnano - Pharmsintez and the Almazov Center agreed to cooperate in the creation of an innovative drug for the personalized diagnosis and treatment of malignant brain neoplasms. Rusnano reported this on June 14, 2023.

The agreement was signed by Ivan Ozhgikhin, Deputy Chairman of the Board of Directors of PJSC Pharmsintez, and Evgeny Shlyakhto, General Director of the National Medical Research Center named after V.A. Almazov, Ministry of Health of Russia.

In accordance with the agreements, Pharmsintez will complete the full cycle of development and production of the required amount of the drug for the first phase of clinical trials.

The project is included in the list of priority tasks of the Federal State Budgetary Institution "National Medical Research Center named after V.A. Almazov" in the direction of "Personalized medicine, high-tech healthcare and health saving technologies."

The next stage will be the conclusion of an agreement that will establish specific parameters and conditions for cooperation in order to implement the agreements reached.

This agreement is the first step of great work to create a qualitatively different drug for the therapy of one of the most serious and dangerous types of cancer. The result will be a completely domestic product that will ensure the independence of our country from imported drugs for the treatment of such diseases, - said Ivan Ozhgikhin.